Lyprinol (stabilised lipid extract of New Zealand green-lipped mussel): a potential preventative treatment modality for inflammatory bowel disease
Date
2005
Authors
Tenikoff, D.
Murphy, K.
Le, M.
Howe, P.
Howarth, G.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Journal of Gastroenterology, 2005; 40(4):361-365
Statement of Responsibility
Danik Tenikoff, Karen J. Murphy, Maria Le, Peter R. Howe and Gordon S. Howarth
Conference Name
Abstract
Lyprinol (Pharmalink International), the stabilised lipid extract of the New Zealand green-lipped mussel, is currently used to relieve symptoms of arthritis. We investigated the effect of pretreatment with Lyprinol (LYP) on experimentally induced inflammatory bowel disease (IBD) in mice. Methods. Male C57BL/6 mice (aged 6 weeks) were gavaged daily for 13 days with (150μl) olive oil (OO; n = 7), fish oil (FO; n = 8), or LYP (n = 8). Mice consumed 2% dextran sulfate sodium (DSS) for 6 days, starting on day 7. Body weight and disease activity index (DAI) scores were recorded daily. Colonic damage was determined by histopathology. Colonic inflammation was quantified by myeloperoxidase (MPO) activity. Results. LYP treatment significantly (P = 0.05) reduced body weight loss, DAI scores, crypt area losses, and cecum and colon weights, compared with FO treatment. MPO activity was not significantly affected by any treatment. Conclusions. These findings provide preliminary evidence that Lyprinol may be potentially useful in ameliorating symptoms of IBD. The benefit, however, is unlikely to be due to the omega-3 fatty acid content. Doseresponse evaluation of Lyprinol in experimental IBD is warranted.
School/Discipline
Dissertation Note
Provenance
Description
The original publication can be found at www.springerlink.com
Access Status
Rights
© Springer-Verlag 2005